Diabetic neuropathies.
Diabetic neuropathy is a common complication of diabetes that is often associated both with considerable morbidity and mortality. The epidemiology and natural course of diabetic neuropathy is clouded with uncertainty, largely due to confusion regarding the definition and measurement of this disorder. The recent resurgence of interest in the vascular hypothesis, oxidative stress, the neurotrophic hypothesis and the possibility of the role of autoimmunity have opened up new avenues of investigation for therapeutic intervention. Paralleling our increased understanding of the pathogenesis of diabetic neuropathy, there must be refinements in our ability to measure quantitatively the different types of defects that occur in this disorder, so that appropriate therapies can be targeted to specific fibre types. These tests must be validated and standardised to allow comparability between studies and a more meaningful interpretation of study results. Our ability to manage successfully the many different manifestations of diabetic neuropathy depends ultimately on our success in uncovering the pathogenic processes underlying this disorder.
Vinik
A I
AI
The Strelitz Diabetes Institutes, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, Virginia 23510, USA.
Park
T S
TS
Stansberry
K B
KB
Pittenger
G L
GL
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000818:Animals; D003929:Diabetic Neuropathies / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008063:Thioctic Acid / Q000627:therapeutic use; D017965:gamma-Linolenic Acid / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D006146:Guanidines; D016756:Immunoglobulins, Intravenous; D008063:Thioctic Acid; D017965:gamma-Linolenic Acid; D000449:Aldehyde Reductase; C004479:pimagedine